Major Mid-Atlantic Insurer Expands Coverage for Nerivio Migraine Device, Providing Access to 3.4 Million Members
Key Insights
A leading mid-Atlantic health insurer has published a new coverage policy for the Nerivio (search) REN wearable, granting reimbursed access to approximately 3.4 million members in Maryland, Washington D.C., and Northern Virginia.
The policy recognizes Nerivio (search) as medically necessary for both acute and preventive migraine (search) treatment in patients ages 8 and older, making it the first non-pharmacological migraine treatment covered by this provider.
With this expansion, approximately 85 million lives across the U.S. now have coverage for Nerivio (search), supported by 25 peer-reviewed studies demonstrating the device's clinical efficacy.
A leading mid-Atlantic health insurance provider has published a new coverage policy for the Nerivio (search) remote electrical neuromodulation (REN) wearable, enabling reimbursed access to approximately 3.4 million members across Maryland, District of Columbia, and Northern Virginia. The policy, which took effect September 1, recognizes the Nerivio REN wearable as medically necessary for both acute and preventive treatment of migraine (search) in patients ages 8 and older.
This coverage decision marks a significant milestone for drug-free migraine (search) treatment, as Nerivio (search) becomes the first and only non-pharmacological therapy for migraine covered by this insurance provider. The expansion reflects a broader national shift toward embracing neuromodulation as an evidence-backed standard of care for migraine management.
Clinical Impact for Pediatric Patients
The coverage expansion holds particular significance for pediatric migraine (search) patients, who have limited therapeutic options. Marc DiSabella, MD, director of the Headache Program at Children's National Hospital in Washington, D.C., emphasized the clinical need: "With migraine, it is important to start with effective treatment early on, before the disease deteriorates in terms of the frequency and severity of migraine attacks. The strong body of clinical evidence supporting the Nerivio (search) REN wearable caught our attention, and many of our patients greatly benefit from this therapy. This is even more critical for young children for whom the range of prescribed therapies is very narrow."
Dr. DiSabella noted that the new policy "removes the economic burden inflicted by a chronic disease such as migraine (search)" for many patients in the region.
Growing Coverage Momentum
The mid-Atlantic coverage decision contributes to expanding national access for Nerivio (search). With this recent policy addition, approximately 85 million lives across the United States now have coverage for the device. Jessica Ailani, MD, a senior headache specialist from the Washington, D.C. area, called for broader adoption: "I hope that this coverage decision will now be followed promptly by the remaining health insurance plans, both commercial and Medicaid, that are still behind in fully understanding the needs of people living with migraine (search)."
The coverage expansion is supported by a substantial evidence base. Lindsay Videnieks, executive director of the Headache and Migraine Policy Forum (search), highlighted that "25 peer-reviewed studies repeatedly and persistently demonstrating the clinical benefits of remote electrical neuromodulation" support the therapy's inclusion in coverage policies.
Safety for Comorbid Conditions
A separate study published in the Journal of Clinical Medicine addresses safety concerns for patients managing both migraine (search) and diabetes (search). The research, titled "Simultaneous Use of Continuous Glucose Monitoring (CGM) Systems and the Remote Electrical Neuromodulation (REN) Wearable for Patients with Comorbid Diabetes and Migraine," demonstrated that Nerivio (search) can be safely used concurrently with the most commonly used CGM systems without disrupting glucose measurement accuracy.
The study examined 21 adults with diabetes (search) using their CGM devices simultaneously with Nerivio (search) during full 45-minute REN sessions. Results showed a median deviation of only 1.6% in glucose readings—well below the prespecified benchmark of 5.0%. Abbott FreeStyle Libre users showed a median deviation of 1.0%, while Dexcom (search) users showed a median deviation of 1.7%.
Christina Treppendahl, certified headache medicine specialist and Medical Science Liaison at Theranica (search), who co-authored the study, noted: "These findings demonstrate that the Nerivio (search) REN wearable and CGM systems can be used together without compromising glucose data integrity—which is critically important for people managing both migraine (search) and diabetes (search)."
Device Technology and Mechanism
The Nerivio (search) REN wearable delivers non-invasive neuromodulation through a smartphone-controlled device that uses gentle electrical pulses on the arm to activate the brain's natural pain regulation system. The FDA-cleared device works by harnessing the body's endogenous Conditioned Pain Modulation (CPM) system to provide both acute symptom relief during migraine (search) attacks and preventive benefits when used regularly.
Dr. Richelle deMayo, chief medical information officer at Connecticut Children's Research Institute (search) and contributing author of the compatibility study, explained the clinical significance: "Migraine (search) treatment can be especially complex for individuals with diabetes (search) because many pharmacologic options carry metabolic or cardiovascular considerations. Nerivio (search) is a drug-free, FDA-cleared wearable that delivers migraine therapy through remote electrical neuromodulation."
Market Access Progress
The coverage expansion represents continued progress in establishing neuromodulation as a standard of care for migraine (search) treatment. The device provides treatment options for patient populations who may not tolerate or prefer to avoid pharmacological approaches, including children, veterans, individuals managing comorbidities, and women of childbearing age.
Theranica (search), the company developing Nerivio (search), reports that the device has been used in more than one million treatments across the United States. The growing body of clinical evidence and expanding insurance coverage positions the technology as an increasingly accessible option for the millions of Americans living with migraine (search).